Cardiac involvement in a case of juvenile dermatomyositis with positive anti‐melanoma differentiation associated protein 5 antibody

Juvenile dermatomyositis (JDM) is an autoimmune disease characterized by muscle weakness and specific skin lesions, as well as non‐muscular involvement such as interstitial lung disease (ILD), cardiac involvement and arthritis. Anti‐melanoma differentiation‐associated protein 5 (anti‐MDA5)‐positive...

Full description

Saved in:
Bibliographic Details
Published in:International journal of rheumatic diseases 2023-08, Vol.26 (8), p.1582-1585
Main Authors: Kaplan, Melike Mehveş, Çelikel, Elif, Güngörer, Vildan, Ekici Tekin, Zahide, Gürsu, Hazım Alper, Polat, Sanem Eryılmaz, Cinel, Güzin, Çelikel Acar, Banu
Format: Article
Language:English
Subjects:
anti‐MDA5
Arrhythmia
Autoantibodies
Autoimmune diseases
cardiac involvement
Cardiomyopathy
Coronary artery disease
Dermatomyositis
Heart diseases
juvenile dermatomyositis
Lung diseases
Melanoma
Myositis
Psoriatic arthritis
Skin diseases
Skin lesions
Ulcers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Juvenile dermatomyositis (JDM) is an autoimmune disease characterized by muscle weakness and specific skin lesions, as well as non‐muscular involvement such as interstitial lung disease (ILD), cardiac involvement and arthritis. Anti‐melanoma differentiation‐associated protein 5 (anti‐MDA5)‐positive JDM patients are typically characterized by the presence of skin ulcers and rapidly progressing ILD (RP‐ILD). Although cardiac involvement is not an expected involvement in anti‐MDA5‐positive JDM cases, it is significant because it can be fatal. In this report, an anti‐MDA5 myositis‐specific autoantibody‐positive JDM case referred with the diagnosis of psoriatic arthritis in whom cardiomyopathy and arrhythmia were detected in follow‐up is presented. Since cardiac involvement is associated with mortality, it would be useful to follow up anti‐MDA5 positive patients for cardiac involvement in addition to lung involvement. Tofacitinib is a promising treatment option in treatment‐resistant JDM.
ISSN:1756-1841
1756-185X
DOI:10.1111/1756-185X.14630